Integra LifeSciences Holdings Corporation (IART) is a Healthcare stock trading at $16.59 (as of 2026-08-20), with a market capitalization of $1.29B. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services. It also sells approximately 40,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
Integra LifeSciences develops and sells surgical implants and medical instruments for neurosurgery, extremity reconstruction, and general surgery, mainly through its Codman Specialty Surgical and Tissue Technologies product lines, generating revenue from sales of specialized surgical products and related offerings.
Earnings power is primarily driven by the Codman Specialty Surgical portfolio, because it is the largest revenue contributor among the company’s two reportable segments, while Tissue Technologies is smaller, making results more sensitive to performance in specialty neurosurgery and instruments.
| Codman Specialty Surgical | $0.3B |
| Tissue Technologies | $0.1B |
Business quality (Weak): Clear two-segment structure and a highly specialized product focus, but operating profitability appears thin based on the latest quarter’s operating margin, which can leave less room for execution or demand swings.
| Price | $16.59 |
| Market Cap | $1.29B |
| EV / EBITDA | 33.0 |
| Price / Book | 1.24 |
| Price / Sales | 0.80 |
| FCF Yield | -2.3% |
| DCF Value (model) | $4.33 |
| DCF Upside vs Price | -73.9% |
| Revenue (TTM) | $1.64B |
| Net Margin | -31.6% |
| Revenue Growth (YoY) | 1.5% |
| EPS Growth (YoY) | 7388.9% |
| FCF Growth (YoY) | -224.4% |
| Altman Z-Score | 0.70 (distress) |
| Piotroski F-Score | 4/9 (moderate) |
| Sector P/E (Healthcare) | 21.6 |
| Industry P/E (Medical Equipment) | 32.9 |
| Top Institutional Holder | BlackRock Fund Advisors ($208.27M) |
| Institutional Holders Tracked | 10 |
| Congressional Trades (recent) | 5 |
| Sector | Healthcare |
| Industry | Medical Equipment |
| CEO | Mojdeh Poul |
| Employees | 4,396 |
| Country | US |
| IPO Date | 1995-08-16 |
Data as of 2026-08-20.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.